Peripheral blood monocyte-expressed ANXA2 gene is involved in pathogenesis of osteoporosis in humans

Fei Yan Deng, Shu Feng Lei, Yan Zhang, Yu Ling Zhang, Yan Peng Zheng, Li Shu Zhang, Rong Pan, Lili Wang, Qing Tian, Hui Shen, Ming Zhao, Yunxia W Lundberg, Yao Zhong Liu, Christopher J. Papasian, Hong Wen Deng

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Low bone mineral density (BMD) is a risk factor of osteoporosis and has strong genetic determination. Genes influencing BMD and fundamental mechanisms leading to osteoporosis have yet to be fully determined. Peripheral blood monocytes (PBM) are potential osteoclast precursors, which could access to bone resorption surfaces and differentiate into osteoclasts to resorb bone. Herein, we attempted to identify osteoporosis susceptibility gene(s) and characterize their function(s), through an initial proteomics discovery study on PBM in vivo, and multiscale validation studies in vivo and in vitro. Utilizing the quantitative proteomics methodology LC-nano-ESI-MS E, we discovered that a novel protein, i.e. ANXA2, was up-regulated twofold in PBM in vivo in Caucasians with extremely low BMD (cases) versus those with extremely high BMD (controls) (n = 28, p < 0.05). ANXA2 gene up-regulation in low BMD subjects was replicated at the mRNA level in PBM in vivo in a second and independent casecontrol sample (n = 80, p < 0.05). At the DNA level, we found that SNPs in the ANXA2 gene were associated with BMD variation in a 3 rd and independent case-control sample (n = 44, p < 0.05), as well as in a random population sample (n = 997, p < 0.05). The above integrative evidence strongly supports the concept that ANXA2 is involved in the pathogenesis of osteoporosis in humans. Through a follow-up cellular functional study, we found that ANXA2 protein significantly promoted monocyte migration across an endothelial barrier in vitro (p < 0.001). Thus, elevated ANXA2 protein expression level, as detected in low BMD subjects, probably stimulates more PBM migration through the blood vessel walls to bone resorption surfaces in vivo, where they differentiate into higher number of osteoclasts and resorb bone at higher rates, thereby decreasing BMD. In conclusion, this study identified a novel osteoporosis susceptibility gene ANXA2, and suggested a novel pathophysiological mechanism, mediated by ANXA2, for osteoporosis in humans.

Original languageEnglish (US)
JournalMolecular and Cellular Proteomics
Volume10
Issue number11
DOIs
StatePublished - Nov 1 2011

Fingerprint

Bone Density
Osteoporosis
Monocytes
Bone
Blood
Genes
Minerals
Osteoclasts
Bone Resorption
Proteomics
Bone and Bones
Proteins
Validation Studies
Single Nucleotide Polymorphism
Blood Vessels
Up-Regulation
Blood vessels
Messenger RNA
DNA
Population

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Molecular Biology

Cite this

Peripheral blood monocyte-expressed ANXA2 gene is involved in pathogenesis of osteoporosis in humans. / Deng, Fei Yan; Lei, Shu Feng; Zhang, Yan; Zhang, Yu Ling; Zheng, Yan Peng; Zhang, Li Shu; Pan, Rong; Wang, Lili; Tian, Qing; Shen, Hui; Zhao, Ming; Lundberg, Yunxia W; Liu, Yao Zhong; Papasian, Christopher J.; Deng, Hong Wen.

In: Molecular and Cellular Proteomics, Vol. 10, No. 11, 01.11.2011.

Research output: Contribution to journalArticle

Deng, FY, Lei, SF, Zhang, Y, Zhang, YL, Zheng, YP, Zhang, LS, Pan, R, Wang, L, Tian, Q, Shen, H, Zhao, M, Lundberg, YW, Liu, YZ, Papasian, CJ & Deng, HW 2011, 'Peripheral blood monocyte-expressed ANXA2 gene is involved in pathogenesis of osteoporosis in humans', Molecular and Cellular Proteomics, vol. 10, no. 11. https://doi.org/10.1074/mcp.M111.011700
Deng, Fei Yan ; Lei, Shu Feng ; Zhang, Yan ; Zhang, Yu Ling ; Zheng, Yan Peng ; Zhang, Li Shu ; Pan, Rong ; Wang, Lili ; Tian, Qing ; Shen, Hui ; Zhao, Ming ; Lundberg, Yunxia W ; Liu, Yao Zhong ; Papasian, Christopher J. ; Deng, Hong Wen. / Peripheral blood monocyte-expressed ANXA2 gene is involved in pathogenesis of osteoporosis in humans. In: Molecular and Cellular Proteomics. 2011 ; Vol. 10, No. 11.
@article{8058f8e4c6b349528989ff2d3ff26e5f,
title = "Peripheral blood monocyte-expressed ANXA2 gene is involved in pathogenesis of osteoporosis in humans",
abstract = "Low bone mineral density (BMD) is a risk factor of osteoporosis and has strong genetic determination. Genes influencing BMD and fundamental mechanisms leading to osteoporosis have yet to be fully determined. Peripheral blood monocytes (PBM) are potential osteoclast precursors, which could access to bone resorption surfaces and differentiate into osteoclasts to resorb bone. Herein, we attempted to identify osteoporosis susceptibility gene(s) and characterize their function(s), through an initial proteomics discovery study on PBM in vivo, and multiscale validation studies in vivo and in vitro. Utilizing the quantitative proteomics methodology LC-nano-ESI-MS E, we discovered that a novel protein, i.e. ANXA2, was up-regulated twofold in PBM in vivo in Caucasians with extremely low BMD (cases) versus those with extremely high BMD (controls) (n = 28, p < 0.05). ANXA2 gene up-regulation in low BMD subjects was replicated at the mRNA level in PBM in vivo in a second and independent casecontrol sample (n = 80, p < 0.05). At the DNA level, we found that SNPs in the ANXA2 gene were associated with BMD variation in a 3 rd and independent case-control sample (n = 44, p < 0.05), as well as in a random population sample (n = 997, p < 0.05). The above integrative evidence strongly supports the concept that ANXA2 is involved in the pathogenesis of osteoporosis in humans. Through a follow-up cellular functional study, we found that ANXA2 protein significantly promoted monocyte migration across an endothelial barrier in vitro (p < 0.001). Thus, elevated ANXA2 protein expression level, as detected in low BMD subjects, probably stimulates more PBM migration through the blood vessel walls to bone resorption surfaces in vivo, where they differentiate into higher number of osteoclasts and resorb bone at higher rates, thereby decreasing BMD. In conclusion, this study identified a novel osteoporosis susceptibility gene ANXA2, and suggested a novel pathophysiological mechanism, mediated by ANXA2, for osteoporosis in humans.",
author = "Deng, {Fei Yan} and Lei, {Shu Feng} and Yan Zhang and Zhang, {Yu Ling} and Zheng, {Yan Peng} and Zhang, {Li Shu} and Rong Pan and Lili Wang and Qing Tian and Hui Shen and Ming Zhao and Lundberg, {Yunxia W} and Liu, {Yao Zhong} and Papasian, {Christopher J.} and Deng, {Hong Wen}",
year = "2011",
month = "11",
day = "1",
doi = "10.1074/mcp.M111.011700",
language = "English (US)",
volume = "10",
journal = "Molecular and Cellular Proteomics",
issn = "1535-9476",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "11",

}

TY - JOUR

T1 - Peripheral blood monocyte-expressed ANXA2 gene is involved in pathogenesis of osteoporosis in humans

AU - Deng, Fei Yan

AU - Lei, Shu Feng

AU - Zhang, Yan

AU - Zhang, Yu Ling

AU - Zheng, Yan Peng

AU - Zhang, Li Shu

AU - Pan, Rong

AU - Wang, Lili

AU - Tian, Qing

AU - Shen, Hui

AU - Zhao, Ming

AU - Lundberg, Yunxia W

AU - Liu, Yao Zhong

AU - Papasian, Christopher J.

AU - Deng, Hong Wen

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Low bone mineral density (BMD) is a risk factor of osteoporosis and has strong genetic determination. Genes influencing BMD and fundamental mechanisms leading to osteoporosis have yet to be fully determined. Peripheral blood monocytes (PBM) are potential osteoclast precursors, which could access to bone resorption surfaces and differentiate into osteoclasts to resorb bone. Herein, we attempted to identify osteoporosis susceptibility gene(s) and characterize their function(s), through an initial proteomics discovery study on PBM in vivo, and multiscale validation studies in vivo and in vitro. Utilizing the quantitative proteomics methodology LC-nano-ESI-MS E, we discovered that a novel protein, i.e. ANXA2, was up-regulated twofold in PBM in vivo in Caucasians with extremely low BMD (cases) versus those with extremely high BMD (controls) (n = 28, p < 0.05). ANXA2 gene up-regulation in low BMD subjects was replicated at the mRNA level in PBM in vivo in a second and independent casecontrol sample (n = 80, p < 0.05). At the DNA level, we found that SNPs in the ANXA2 gene were associated with BMD variation in a 3 rd and independent case-control sample (n = 44, p < 0.05), as well as in a random population sample (n = 997, p < 0.05). The above integrative evidence strongly supports the concept that ANXA2 is involved in the pathogenesis of osteoporosis in humans. Through a follow-up cellular functional study, we found that ANXA2 protein significantly promoted monocyte migration across an endothelial barrier in vitro (p < 0.001). Thus, elevated ANXA2 protein expression level, as detected in low BMD subjects, probably stimulates more PBM migration through the blood vessel walls to bone resorption surfaces in vivo, where they differentiate into higher number of osteoclasts and resorb bone at higher rates, thereby decreasing BMD. In conclusion, this study identified a novel osteoporosis susceptibility gene ANXA2, and suggested a novel pathophysiological mechanism, mediated by ANXA2, for osteoporosis in humans.

AB - Low bone mineral density (BMD) is a risk factor of osteoporosis and has strong genetic determination. Genes influencing BMD and fundamental mechanisms leading to osteoporosis have yet to be fully determined. Peripheral blood monocytes (PBM) are potential osteoclast precursors, which could access to bone resorption surfaces and differentiate into osteoclasts to resorb bone. Herein, we attempted to identify osteoporosis susceptibility gene(s) and characterize their function(s), through an initial proteomics discovery study on PBM in vivo, and multiscale validation studies in vivo and in vitro. Utilizing the quantitative proteomics methodology LC-nano-ESI-MS E, we discovered that a novel protein, i.e. ANXA2, was up-regulated twofold in PBM in vivo in Caucasians with extremely low BMD (cases) versus those with extremely high BMD (controls) (n = 28, p < 0.05). ANXA2 gene up-regulation in low BMD subjects was replicated at the mRNA level in PBM in vivo in a second and independent casecontrol sample (n = 80, p < 0.05). At the DNA level, we found that SNPs in the ANXA2 gene were associated with BMD variation in a 3 rd and independent case-control sample (n = 44, p < 0.05), as well as in a random population sample (n = 997, p < 0.05). The above integrative evidence strongly supports the concept that ANXA2 is involved in the pathogenesis of osteoporosis in humans. Through a follow-up cellular functional study, we found that ANXA2 protein significantly promoted monocyte migration across an endothelial barrier in vitro (p < 0.001). Thus, elevated ANXA2 protein expression level, as detected in low BMD subjects, probably stimulates more PBM migration through the blood vessel walls to bone resorption surfaces in vivo, where they differentiate into higher number of osteoclasts and resorb bone at higher rates, thereby decreasing BMD. In conclusion, this study identified a novel osteoporosis susceptibility gene ANXA2, and suggested a novel pathophysiological mechanism, mediated by ANXA2, for osteoporosis in humans.

UR - http://www.scopus.com/inward/record.url?scp=80555136778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80555136778&partnerID=8YFLogxK

U2 - 10.1074/mcp.M111.011700

DO - 10.1074/mcp.M111.011700

M3 - Article

C2 - 21817168

AN - SCOPUS:80555136778

VL - 10

JO - Molecular and Cellular Proteomics

JF - Molecular and Cellular Proteomics

SN - 1535-9476

IS - 11

ER -